Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Johnson & Johnson (NYSE:JNJ) with a Outperform ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...

Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...

On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (SNSE:ABBVCL) with a Outperform recommendation. What is the Fund Sentiment? There are 4,922 funds or ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform recommendation. As of October 22, 2024, the average one-year price ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...